Detalles de la búsqueda
1.
Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.
Future Oncol
; 15(13): 1481-1491, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30839234
2.
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Cancer
; 120(8): 1145-54, 2014 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24501009
3.
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.
Lancet Haematol
; 2024 Jun 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38889737
4.
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors.
Clin Cancer Res
; 23(5): 1177-1185, 2017 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27733479
5.
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
Lung Cancer
; 106: 76-82, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28285698
6.
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
J Thorac Oncol
; 9(10): 1523-31, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25521398
7.
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
Clin Breast Cancer
; 11(2): 82-92, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21569994
Resultados
1 -
7
de 7
1
Próxima >
>>